Client NewsOKYO Pharma Limited: Closing of Offering
London and New York, 19 May 2022 – OKYO Pharma Limited (LSE: OKYO; Nasdaq: OKYO) (“OKYO” or the “Company”), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce the closing of its initial public offering of 625,000 American Depositary Shares (“ADSs”) representing 40,625,000 of the Company’s ordinary shares of no par value each (“Ordinary Shares”) (the “Offering”) at a price of $4.00 per ADS, for aggregate proceeds of approximately $2,500,000, before deducting underwriting discounts and commissions. Each ADS offered in the Offering represents 65 Ordinary Shares.
OKYO’s ADSs are trading on the Nasdaq Capital Market under the ticker symbol “OKYO”.
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.